Gastrointestinal Stromal Tumors of the Colon and Rectum.

Paek, Ok Joo; Kim, Young Bae; Oh, Seung Yeop; Suh, Kwang Wook

doi:10.3393/jksc.2009.25.5.318

Articles

Page Path: HOME > J Korean Soc Coloproctol > Volume 25(5); 2009 > Article

Original Article
Gastrointestinal Stromal Tumors of the Colon and Rectum.: Paek, Ok Joo , Kim, Young Bae , Oh, Seung Yeop , Suh, Kwang Wook; Journal of the Korean Society of Coloproctology 2009;25(5):318-322
DOI: https://doi.org/10.3393/jksc.2009.25.5.318

¹Department of Surgery, Ajou University School of Medicine, Suwon, Korea. suhkw@ajou.ac.kr
²Department of Pathology, Ajou University School of Medicine, Suwon, Korea.

prev next

2,680 Views
15 Download
3 Crossref
3 Scopus

Full Article

Download PDF

Abstract

PURPOSE
This study was designed to review the clinical characteristics of gastrointestinal stromal tumors (GISTs) of the colon and rectum and to evaluate their immunohistochemical and pathologic features based on the current National Institutes of Health criteria.
METHODS
Patient and disease characteristics, pathologic features, surgical or endoscopic management, and clinical outcomes of 11 patients with GISTs diagnosed and primarily treated at our institution between March 1995 and February 2009 were evaluated.
RESULTS
Colorectal GISTs accounted for 4.4% of all GISTs. The primary location was the rectum (8 cases). Four patients had high-risk GISTs, 4 patients had low-risk GISTs, and 3 patients had very low-risk GISTs. All tumors were c-kit positive. Four patients underwent a radical resection, whereas 7 patients underwent an endoscopic resection (n=3) or a transanal excision (n=4). Two high-risk patients without adjuvant Imatinib mesylate therapy developed metastases, but the other high-risk patients with adjuvant Imatinib mesylate therapy didn't.
CONCLUSION
Colorectal GISTs occurred predominantly in the rectum. Because GISTs do not metastasize through the lymphatics, small GISTs that are amenable to local excision or endoscopic resection can be treated by either of these techniques as long as negative microscopic margins are obtained around the primary tumor. Patients with high-risk GISTs should be considered for the use of Imatinib mesylate as adjuvant therapy.

Keywords: GIST (gastrointestinal stromal tumor);Submucosal tumor;C-kit

Figure & Data

References

Citations

Citations to this article as recorded by

Transanal endoscopic microsurgery with alternative neoadjuvant imatinib for localized rectal gastrointestinal stromal tumor: a single center experience with long-term surveillance
Xueshan Bai, Weixun Zhou, Yunhao Li, Guole Lin
Surgical Endoscopy.2021; 35(7): 3607. CrossRef
Primary localized rectal/pararectal gastrointestinal stromal tumors: results of surgical and multimodal therapy from the French Sarcoma group
Thanh-Khoa Huynh, Pierre Meeus, Philippe Cassier, Olivier Bouché, Sophie Lardière-Deguelte, Antoine Adenis, Thierry André, Julien Mancini, Olivier Collard, Michael Montemurro, Emmanuelle Bompas, Maria Rios, Nicolas Isambert, Didier Cupissol, Jean-Yves Bla
BMC Cancer.2014;[Epub] CrossRef
Efficacy of Imatinib Mesylate Neoadjuvant Treatment for a Locally Advanced Rectal Gastrointestinal Stromal Tumor
Kyu Jong Yoon, Nam Kyu Kim, Kang Young Lee, Byung Soh Min, Hyuk Hur, Jeonghyun Kang, Sarah Lee
Journal of the Korean Society of Coloproctology.2011; 27(3): 147. CrossRef

Cited

Related articles